You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 41 - 50 of 204654 results
  1. Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease

    SBC: Metselex, Incorporated            Topic: 105

    ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Treatment of Inflammatory Complications of Respiratory Infection

    SBC: Respana Therapeutics, Inc            Topic: NIAID

    Abstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing

    SBC: TWINSTRAND BIOSCIENCES INC            Topic: NCI

    Problem: With a 5-year survival of ~30%, AML is the 6th deadliest cancer, and rt20,000 new patients are diagnosed each year in the United States. Although most patients achieve Complete Remission (CR) with aggressive therapy, most will eventually relapse. The criteria for CR, however, is based on historical diagnostic methods, and patients in CR may carry up to 1010 residual leukemia blasts. Signi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Neuro-exergaming for the Prevention and Remediation of Decline due to Parkinson's Disease: Clinical Trial of the Interactive Physical and Cognitive Exercise System (iPACES v3)

    SBC: iPACES LLC            Topic: NINDS

    PROJECT SUMMARY/ABSTRACT Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer’s disease with prevalence estimated at 0.3% in the general population and at 1% in individuals over age 60 (Getz and Levin, 2017). In addition to the cardinal motor features associated with this illness, individuals with PD also experience cognitive decline. While estimates ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. The first clinical use of the BiVACOR Total Artificial Heart

    SBC: BIVACOR INC            Topic: NHLBI

    SUMMARY/ABSTRACT Heart Failure (HF) is a devastating epidemic affecting more than 23 million patients worldwide; in the U.S. alone, 1,000,000 new cases are reported each year. While heart transplantation provides the best treatment option for many patients, less than 6,000 procedures take place globally each year. Consequently, it is estimated that 50,000 – 100,000 patients could immediately ben ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Mitigation of Radiation Induced Gastrointestinal Syndrome.

    SBC: BCN BIOSCIENCES LLC            Topic: NIAID

    Abstract: Currently RAS has been considered a high value target in cancer drug development considering that over 30 percent of all human cancers – including 95% of pancreatic cancers and 45% of colorectal cancers — are driven by mutations of the RAS family of genes. The first clinical launch of a G12C KRAS inhibitor is Lumakras™ (sotorasib) from Amgen for non-small cell lung carcinoma and Mi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Software for the complete characterization of antibody repertoires: from germline and mRNA sequence assembly to deep learning predictions of their protein structures and targets

    SBC: DNASTAR, INC.            Topic: 400

    The B cell population in each individual produces an estimated 1010 different antibodies, collectively known as the antibody repertoire. This extraordinary diversity is essential for responding to the unique history of infections, vaccinations and cancer encountered over an individual’s lifetime. Conversely, regulatory errors in the system play a pivotal role in a host of auto-immune diseases. A ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of World's First Fully Human Broad Spectrum Anti-Snake Venom

    SBC: Centivax Inc            Topic: NIAID

    ABSTRACT Snakebite envenoming poses a global risk to human health. For over 125 years, antivenoms have consisted of animal-derived polyclonal serum immunoglobulin G (IgG). In recent decades, IgG digested into antigen-binding fragments Fab(2) has been found to reduce some of the most severe side-effects of non-human antivenom. These antivenoms are obtained by immunizing horses or sheep with individ ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Therapy and Prophylaxis for Genital Tract Infection

    SBC: THERAPYX, INC.            Topic: NIAID

    ABSTRACT GneX12 is a patented therapeutic vaccine in development specifically for women with Neisseria gonorrhoeae (gonorrhea) infection. It is a novel formulation of recombinant human interleukin-12 (IL-12) encapsulated in biodegradable sustained release micro-particles. It is meant to be given in conjunction with standard of care antibiotics to turn infections into live vaccines that generate pr ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Highly Multiplexed Single Molecule Tethering

    SBC: SCANOGEN INC.            Topic: NIAID

    Highly Multiplexed Single Molecule Tethering Summary Bloodstream infections in patients with sepsis symptoms should be promptly treated with antibiotics; however, the time required to identify pathogens using methods based on blood culture is a major obstacle to timely effective antimicrobial therapy. The development of a comprehensive molecular assay capable of identifying microbes directly from ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government